Generation Bio Co.
Develops siRNA therapeutics delivered via ctLNPs for T cell-driven autoimmune diseases.
GBIO | US
Overview
Corporate Details
- ISIN(s):
- US37148K1007
- LEI:
- Country:
- United States of America
- Address:
- 301 BINNEY STREET, 2142 CAMBRIDGE
- Website:
- https://generationbio.com/
- Sector:
- Manufacturing
Description
Generation Bio Co. is a biotechnology company developing therapeutics for T cell-driven autoimmune diseases. The company's platform utilizes proprietary cell-targeted lipid nanoparticles (ctLNPs) to selectively deliver small interfering RNA (siRNA) to T cells. This approach is designed to potently silence specific genes and modulate the function of autoreactive T cells responsible for tissue and organ damage. The technology aims to provide redosable treatments with genetic precision and tunable pharmacology, while sparing the broader immune system from off-target effects.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Generation Bio Co. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Generation Bio Co.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Generation Bio Co. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
